Clinical Trials
5 trialsNCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT05398640 2026-04-20
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
Iovance Biotherapeutics, Inc.
Available
NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT04853602 2024-08-12
IFx-Hu2.0 Expanded Access Program
TuHURA Biosciences, Inc.
Available
NCT04960891 2022-01-21
Non Applicable
Immunocore Ltd
Available